MEN WITH LOCALLY OR REGIONALLY ADVANCED PROSTATE CANCER WHO RECEIVE R ADICAL
PROSTATECTOMY FOLLOWED BY R ADIATION THER APY LIVE LONGER THAN THOSE WHO RECEIVE
R ADIATION THER APY PLUS ANDROGEN DEPRIVATION THER APY (ADT), ACCORDING TO A RECENT STUDY.
CLINICAL GUIDELINES IN the U.S. a nd
Europe ca ll for the use of combination
therapy for men with high-risk prostate
ca ncer, but there has been a dea r th of
evidence as to which of two commonly
used mu ltimoda l therapies — radica l
prostatectomy plus radiation therapy
a nd radiation therapy plus A DT — is
more ef fective, according to Thoma s
Jang, MD, MPH, FACS, urologic oncolo-
gist at Rutgers Ca ncer Institute of New
Jersey. Dr. Ja ng, Grace Lu-Yao, Ph D,
MPH, Associate Director of Population
Science at the Sidney Kimmel Ca ncer
Center at Thomas Jefferson University
in Philadelphia, and a group of research-
ers set out to cha nge that.
PROCEDURAL RENAISSANCE?
Usi n g pat ient i n for mat ion f rom t he
SEER–Medicare database, researchers
More Aggressive
Combination Therapy
Offers Survival Advantage
for High-Risk Prostate
Cancer Patients
BY THOMAS CROCKER
1 4
